SI2827845T1 - Sestavki, ki obsegajo dostavno sredstvo in njihova priprava - Google Patents

Sestavki, ki obsegajo dostavno sredstvo in njihova priprava

Info

Publication number
SI2827845T1
SI2827845T1 SI201331386T SI201331386T SI2827845T1 SI 2827845 T1 SI2827845 T1 SI 2827845T1 SI 201331386 T SI201331386 T SI 201331386T SI 201331386 T SI201331386 T SI 201331386T SI 2827845 T1 SI2827845 T1 SI 2827845T1
Authority
SI
Slovenia
Prior art keywords
compositions
preparation
delivery agent
delivery
agent
Prior art date
Application number
SI201331386T
Other languages
English (en)
Slovenian (sl)
Inventor
Thomas Vilhelmsen
Original Assignee
Novo Nordisk A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49221869&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI2827845(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novo Nordisk A/S filed Critical Novo Nordisk A/S
Publication of SI2827845T1 publication Critical patent/SI2827845T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A61K31/609—Amides, e.g. salicylamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SI201331386T 2012-03-22 2013-03-15 Sestavki, ki obsegajo dostavno sredstvo in njihova priprava SI2827845T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP12160742 2012-03-22
US201361748844P 2013-01-04 2013-01-04
EP13153422 2013-01-31
EP13709232.6A EP2827845B1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof
PCT/EP2013/055363 WO2013139695A1 (en) 2012-03-22 2013-03-15 Compositions comprising a delivery agent and preparation thereof

Publications (1)

Publication Number Publication Date
SI2827845T1 true SI2827845T1 (sl) 2019-04-30

Family

ID=49221869

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201331386T SI2827845T1 (sl) 2012-03-22 2013-03-15 Sestavki, ki obsegajo dostavno sredstvo in njihova priprava

Country Status (11)

Country Link
US (1) US10335369B2 (cg-RX-API-DMAC7.html)
EP (3) EP2827845B1 (cg-RX-API-DMAC7.html)
JP (1) JP6356660B2 (cg-RX-API-DMAC7.html)
CN (3) CN104203221A (cg-RX-API-DMAC7.html)
ES (1) ES2965469T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20231613T1 (cg-RX-API-DMAC7.html)
HU (1) HUE064694T2 (cg-RX-API-DMAC7.html)
PL (2) PL3542790T3 (cg-RX-API-DMAC7.html)
RS (2) RS58636B1 (cg-RX-API-DMAC7.html)
SI (1) SI2827845T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013139695A1 (cg-RX-API-DMAC7.html)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
MY161450A (en) 2011-04-12 2017-04-14 Novo Nordisk As Double-acylated glp-1 derivatives
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
DK2827845T3 (en) * 2012-03-22 2019-04-01 Novo Nordisk As COMPOSITIONS INCLUDING A PROCEDURE AND PREPARING THEREOF
EP4324475A1 (en) * 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1
CN104173313B (zh) * 2014-08-25 2017-05-17 杭州朱养心药业有限公司 利伐沙班片剂药物组合物
CN107427469B (zh) 2015-01-12 2021-01-26 安特里斯生物制药公司 固体口服剂型
CN108883073B (zh) * 2016-12-30 2021-10-08 江苏恒瑞医药股份有限公司 一种glp-1类似物的药物组合物及其制备方法
TWI797133B (zh) 2017-06-09 2023-04-01 丹麥商諾佛 儂迪克股份有限公司 用於經口投予的固體組成物
JP6898518B2 (ja) 2018-02-02 2021-07-07 ノヴォ ノルディスク アー／エス Ｇｌｐ−１アゴニスト、ｎ−（８−（２−ヒドロキシベンゾイル）アミノ）カプリル酸の塩及び滑沢剤を含む固形組成物
TWI829687B (zh) 2018-05-07 2024-01-21 丹麥商諾佛 儂迪克股份有限公司 包含glp-1促效劑與n-(8-(2-羥基苯甲醯基)胺基)辛酸之鹽的固體組成物
CN113329810A (zh) * 2019-01-24 2021-08-31 诺和诺德股份有限公司 辊压机和使用辊压机的干法制粒方法
KR20220046565A (ko) * 2019-08-07 2022-04-14 노보 노르디스크 에이/에스 Egf(a) 유도체 및 n-(8-(2-하이드록시벤조일)아미노)카프릴산의 염을 포함하는 고형 조성물
EP4025192B1 (en) 2019-09-02 2025-12-03 Novo Nordisk A/S Process for producing a tablet comprising glp-1 peptides
WO2021043971A1 (en) 2019-09-06 2021-03-11 Novo Nordisk A/S Method and equipment for fractionation of granules for use in pharmaceutical compositions
EP4054536A1 (en) 2019-11-07 2022-09-14 Novo Nordisk A/S Solid compositions comprising a glp-1 agonist, an sglt2 inhibitor and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
CN115461044B (zh) * 2020-04-29 2025-06-10 诺和诺德股份有限公司 包含glp-1激动剂和组氨酸的固体组合物
CN111517980B (zh) * 2020-05-14 2021-02-09 台州浦凯医药科技有限公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钾晶型化合物、制备方法及用途
IL299701A (en) * 2020-07-22 2023-03-01 Novo Nordisk As GLP-1 and GIP receptor co-agonists suitable for oral administration
TW202214679A (zh) * 2020-07-22 2022-04-16 丹麥商諾佛 儂迪克股份有限公司 Glp-1及gip受體共促效劑
CN113117050B (zh) * 2021-05-06 2022-04-26 合肥天汇孵化科技有限公司 多肽组合物及其用途
IL308280A (en) 2021-05-07 2024-01-01 Lilly Co Eli Tablet worn out
JP2024525377A (ja) 2021-07-15 2024-07-12 ノヴォ ノルディスク アー／エス Ｎ－（８－（２－ヒドロキシベンゾイル）アミノ）カプリル酸の塩を含む錠剤
AU2022401780A1 (en) * 2021-12-01 2024-07-04 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Pharmaceutical composition of glp-1 and gip receptor dual agonist and use thereof
TW202330584A (zh) 2022-01-20 2023-08-01 丹麥商諾佛 儂迪克股份有限公司 前藥及其用途
CN114984191B (zh) * 2022-07-04 2022-10-25 北京惠之衡生物科技有限公司 一种多肽类药物口服递送组合物
TW202421645A (zh) 2022-11-25 2024-06-01 丹麥商諾佛 儂迪克股份有限公司 如ｇｌｐ—１之肽治療劑的口服投與

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4609675A (en) 1984-08-17 1986-09-02 The Upjohn Company Stable, high dose, high bulk density ibuprofen granulations for tablet and capsule manufacturing
US4918098A (en) 1986-03-12 1990-04-17 American Cyanamid Company Macrolide compounds
DK39892D0 (da) 1992-03-25 1992-03-25 Bernard Thorens Peptid
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5650386A (en) 1995-03-31 1997-07-22 Emisphere Technologies, Inc. Compositions for oral delivery of active agents
US5866536A (en) 1995-03-31 1999-02-02 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
DE69737479T4 (de) 1996-08-30 2010-05-06 Novo Nordisk A/S Glp-1 derivate
US5773647A (en) 1997-02-07 1998-06-30 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO1999043707A1 (en) 1998-02-27 1999-09-02 Novo Nordisk A/S N-terminally modified glp-1 derivatives
EP1056775B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Glp-1 derivatives of glp-1 and exendin with protracted profile of action
EP1061946B1 (en) 1998-02-27 2004-04-28 Novo Nordisk A/S Glp-1 derivatives with helix-content exceeding 25 %, forming partially structured micellar-like aggregates
ATE466027T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Abkömmlinge von glp-1 analogen
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
AU3357800A (en) 1999-02-05 2000-08-25 Emisphere Technologies, Inc. Method of preparing alkylated salicylamides
WO2000048589A1 (en) 1999-02-22 2000-08-24 Emisphere Holdings, Inc. Solid oral dosage form containing heparin or a heparinoid in combination with a carrier
JP2002537321A (ja) 1999-02-22 2002-11-05 エラン コーポレイション ピーエルスィー 促進剤を含む固体経口剤形
US7658938B2 (en) 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
GB9923436D0 (en) 1999-10-04 1999-12-08 American Home Prod Pharmaceutical compositions
US6793934B1 (en) 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
WO2001092206A1 (en) 2000-06-02 2001-12-06 Emisphere Technologies, Inc. Method of preparing salicylamides
US7049283B2 (en) 2000-12-06 2006-05-23 Novartis Ag Pharmaceutical compositions for the oral delivery of pharmacologically active agents
MXPA03008837A (es) 2001-03-27 2004-05-05 Ranbaxy Lab Ltd Una composicion farmaceutica estable de pravastatina.
PL366728A1 (en) 2001-05-15 2005-02-07 Warner-Lambert Company Llc Compaction process for manufacture of sodium phenytoin dosage form
US20030068356A1 (en) 2001-07-10 2003-04-10 Pather S. Indiran Sequential drug delivery systems
AU2002352974A1 (en) 2001-11-29 2003-06-10 Emisphere Technologies, Inc. Formulations for oral administration of cromolyn sodium
WO2003063838A1 (en) 2002-02-01 2003-08-07 Pfizer Products Inc. Dry granulated formulations of azithromycin
JP4417113B2 (ja) 2002-02-20 2010-02-17 エミスフェアー・テクノロジーズ・インク Ｇｌｐ−１分子の投与方法
JP2004131398A (ja) 2002-10-08 2004-04-30 Taihei Chemical Industrial Co Ltd 錠剤用滑沢剤
CA2525168A1 (en) 2003-05-14 2004-12-02 Emisphere Technologies, Inc. Compositions for delivering peptide yy and pyy agonists
PL1651248T3 (pl) 2003-07-11 2010-02-26 Novartis Ag Doustnie dawkowana kompozycja farmaceutyczna zawierająca środek dostarczający w postaci mikronizowanej
JP4949838B2 (ja) 2003-09-19 2012-06-13 ノヴォ ノルディスク アー／エス 新規ｇｌｐ−１誘導体
EP1704165B1 (en) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1 compounds
AU2004298425A1 (en) 2003-12-18 2005-06-30 Novo Nordisk A/S Novel GLP-1 analogues linked to albumin-like agents
US20060286129A1 (en) 2003-12-19 2006-12-21 Emisphere Technologies, Inc. Oral GLP-1 formulations
WO2005099672A1 (en) 2004-04-13 2005-10-27 Ranbaxy Laboratories Limited A modified release pharmaceutical formulation comprising amoxicillin and clavulanate
JP2007536268A (ja) * 2004-05-06 2007-12-13 エミスフェアー・テクノロジーズ・インク 固体剤形の湿性ヘパリン
CN102040536B (zh) 2004-05-06 2013-06-19 爱密斯菲尔科技公司 N-[8-(2-羟基苯甲酰基)氨基]辛酸一钠的晶体的多晶
EP1756039B1 (en) 2004-05-14 2012-10-17 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
CN1767818A (zh) 2004-05-31 2006-05-03 三亚药品株式会社 含β－内酰胺抗生素的分散片剂及其制备方法
CN101010339B (zh) 2004-07-02 2011-11-09 布里斯托尔-迈尔斯斯奎布公司 人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
ES2564167T3 (es) 2004-07-08 2016-03-18 Novo Nordisk A/S Conjugados de polipéptidos de acción prolongada que contienen una fracción tetrazol
EP1781257B1 (en) 2004-08-13 2018-12-19 Emisphere Technologies, Inc. Pharmaceutical formulations containing microparticles or nanoparticles of a delivery agent
WO2006037811A2 (en) 2004-10-07 2006-04-13 Novo Nordisk A/S Protracted exendin-4 compounds
US7893017B2 (en) 2004-10-07 2011-02-22 Novo Nordisk A/S Protracted GLP-1 compounds
NZ555120A (en) 2004-12-03 2009-11-27 Merck & Co Inc Pharmaceutical formulation of carboxamide HIV integrase inhibitors containing a release rate controlling composition
EP1843755B1 (en) 2005-02-01 2015-04-01 Emisphere Technologies, Inc. Gastric retention and controlled release delivery system
TWI362392B (en) 2005-03-18 2012-04-21 Novo Nordisk As Acylated glp-1 compounds
KR20070120112A (ko) 2005-03-18 2007-12-21 노보 노르디스크 에이/에스 연장형 ｇｌｐ-1 화합물
US20080260818A1 (en) 2005-03-28 2008-10-23 Dexcel Pharma Technologies Ltd. Controlled Absorption of Statins in the Intestine
US20070049557A1 (en) 2005-08-24 2007-03-01 Hashim Ahmed Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers
KR101432313B1 (ko) 2005-11-17 2014-08-20 노파르티스 아게 약제학적 조성물
BRPI0710503A2 (pt) 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US8927015B2 (en) 2006-04-12 2015-01-06 Emisphere Technologies, Inc. Formulations for delivering insulin
JP2009539862A (ja) 2006-06-09 2009-11-19 メリオン リサーチ Ｉｉｉ リミテッド 強化剤を含む固体経口投与剤形
EP2040718B1 (en) * 2006-06-28 2017-12-27 Emisphere Technologies, Inc. Gallium nitrate formulations
ES2296529B1 (es) 2006-08-07 2009-04-01 Laboratorios Farmaceuticos Rovi, S.A. Composicion farmaceutica con promotores de absorcion.
EP2057189B1 (en) 2006-08-25 2013-03-06 Novo Nordisk A/S Acylated exendin-4 compounds
JP5021033B2 (ja) 2006-09-07 2012-09-05 エフ．ホフマン−ラ ロシュ アーゲー Ｓｎａｃ（サルカプロザートナトリウム）の製造法
AR062925A1 (es) 2006-09-22 2008-12-17 Novartis Ag Metodo para fabricar tabletas que contienen agentes farmacologicamente activos
WO2008070547A1 (en) 2006-12-01 2008-06-12 Emisphere Technologies Inc. Improved acyclovir formulations
PL2131810T3 (pl) 2007-03-02 2011-09-30 Novartis Ag Podawanie doustne kalcytoniny
US20110183889A1 (en) 2007-08-29 2011-07-28 The Regents Of The University Of California Salicylanilide modified peptides for use as oral therapeutics
WO2009030771A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
CN101842386A (zh) 2007-09-05 2010-09-22 诺沃-诺迪斯克有限公司 截短的glp-1衍生物和它们的治疗用途
WO2009030738A1 (en) 2007-09-05 2009-03-12 Novo Nordisk A/S Glucagon-like peptide-1 derivatives and their pharmaceutical use
MX2010003979A (es) 2007-10-16 2010-06-02 Biocon Ltd Composicion farmaceutica oralmente administrable y proceso para su preparacion.
MX2010004716A (es) 2007-11-02 2010-12-17 Emisphere Tech Inc Metodo para tratar la deficiencia de vitamina b12.
US20090124639A1 (en) * 2007-11-06 2009-05-14 Emisphere Technologies Inc. valacyclovir formulations
US20100317057A1 (en) * 2007-12-28 2010-12-16 Novo Nordisk A/S Semi-recombinant preparation of glp-1 analogues
NZ591497A (en) * 2008-08-18 2012-11-30 Entera Bio Ltd A compositions comprising a protein, a protease inhibitor and N-(8-[2-hydroxybenzoyl]amino)caprylate (SNAC) or N-(10[2-hydroxybenzoyl]amino)decanoate (SNAD) for diabetes mellitus treatment
CN117547538A (zh) 2009-02-13 2024-02-13 勃林格殷格翰国际有限公司 包含dpp-4抑制剂(利格列汀)任选地组合其它抗糖尿病药的抗糖尿病药物
AU2010339907A1 (en) 2009-12-16 2012-07-05 Nod Pharmaceuticals, Inc. Compositions and methods for oral drug delivery
US20110182985A1 (en) 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
WO2011109787A1 (en) 2010-03-05 2011-09-09 Conjuchem, Llc Methods of administering insulinotropic peptides
WO2011116139A2 (en) 2010-03-16 2011-09-22 Chiasma Inc. Improved pharmaceutical compositions and methods of delivery
AR081760A1 (es) 2010-04-07 2012-10-17 Vertex Pharma Una composicion farmaceutica para administracion oral que comprende acido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benzoico, un metodo para producir la misma, una tableta y una forma unitaria de dosificacion oral que la comprende y el uso de la misma para la fabricacion de un medicamento
CN107961377B (zh) 2010-05-05 2022-11-22 勃林格殷格翰国际有限公司 组合疗法
DE202010015867U1 (de) 2010-11-25 2011-05-05 Buchhalter, Thomas Elektromechanische Halterung zur Aufnahme von Navigations- und Kommunikationsgeräte im KFZ
PT2651398T (pt) 2010-12-16 2018-03-09 Novo Nordisk As Composições sólidas compreendendo um agonista de glp-1 e um sal de ácido n-(8-(2-hidroxibenzoil)amino) caprílico
EP4324475A1 (en) 2012-03-22 2024-02-21 Novo Nordisk A/S Compositions of glp-1 peptides and preparation thereof
EP2827845B1 (en) 2012-03-22 2018-12-26 Novo Nordisk A/S Compositions comprising a delivery agent and preparation thereof
CN104487056A (zh) 2012-06-20 2015-04-01 诺和诺德A/S（股份有限公司） 包含肽和递送剂的片剂制剂
PL2991671T3 (pl) 2013-05-02 2019-01-31 Novo Nordisk As Doustne dawkowanie związków glp-1

Also Published As

Publication number Publication date
HUE064694T2 (hu) 2024-04-28
CN104203221A (zh) 2014-12-10
EP2827845B1 (en) 2018-12-26
CN111494324B (zh) 2023-05-16
US20150031606A1 (en) 2015-01-29
EP4331667A3 (en) 2024-05-08
JP2015515459A (ja) 2015-05-28
WO2013139695A1 (en) 2013-09-26
EP2827845A1 (en) 2015-01-28
EP3542790A1 (en) 2019-09-25
PL3542790T3 (pl) 2024-02-26
PL2827845T3 (pl) 2019-06-28
JP6356660B2 (ja) 2018-07-11
ES2965469T3 (es) 2024-04-15
RS58636B1 (sr) 2019-05-31
RS64942B1 (sr) 2024-01-31
CN111494323A (zh) 2020-08-07
US10335369B2 (en) 2019-07-02
CN111494324A (zh) 2020-08-07
EP3542790C0 (en) 2023-09-13
HRP20231613T1 (hr) 2024-03-15
EP4331667A2 (en) 2024-03-06
CN111494323B (zh) 2023-03-28
EP3542790B1 (en) 2023-09-13

Similar Documents

Publication Publication Date Title
PL2827845T3 (pl) Kompozycje zawierające substancję dostarczającą i ich wytwarzanie
IL286348A (en) Pharmaceutical preparations that include allopregnanolone
IL253870B (en) Certain amino-pyrimidines and pharmaceutical preparations containing them
ZA201703992B (en) Inhalable pharmaceutical compositions
IL236268B (en) Preparations for mucosal administration and their uses
IL236358B (en) Medicinal preparations containing hormone replacements and their use
IL236024A (en) The history of benzimidazole-proline and its pharmaceutical preparations
ZA201402988B (en) Dermal Delivery Compositions and Methods
PT2827845T (pt) Composições compreendendo um agente de entrega e sua preparação
IL252566B (en) Pharmacy preparations and methods
SG10202112138QA (en) Compositions comprising peg and sulphate
EP2753341A4 (en) ANTIMICROBIAL COMPOSITIONS AND USES THEREOF
SG11201404123XA (en) Medicament delivery devices
IL233825A (en) H1-indazole-3-carboxamide compounds, preparations containing them and their use in the preparation of medicines
EP2685993A4 (en) PHARMACEUTICAL COMPOSITIONS AND TOPICAL USE THEREOF
IL235830A0 (en) New dosage and formulation
EP2668044A4 (en) COMPOSITIONS AND THEIR USE
EP2874641A4 (en) COMPOSITIONS INCREASING THE GLUTATHION RATE AND USES THEREOF
PL2908837T3 (pl) Kompozycje do dostarczania leku
ZA201307837B (en) Compositions comprising antibacterial agent and tazobactam
IL226554A (en) Medicinal preparations containing alisporiovir
ZA201504512B (en) Pharmaceutical composition comprising desloratadine and prednisolone and use thereof
GB201208315D0 (en) Pharmaceutical methods and compositions
GB201110598D0 (en) Pharmaceutical compositions and devices
GB201219884D0 (en) New composition and preparation thereof